Case Report

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

Alessio Cortellini,1,2 Alessandro Parisi,1,2 Maria Concetta Fargnoli,2,3 Katia Cannita,2 Azzurra Irelli,1,2 Giampiero Porzio,1,2 Claudio Martinazzo,4 and Corrado Ficorella1,2

1Medical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy
2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
3Oncological Dermatology Unit, St. Salvatore Hospital, L’Aquila, Italy
4Department of Neurophysiopathology, St. Salvatore Hospital, L’Aquila, Italy

Correspondence should be addressed to Alessio Cortellini; alessiocortellini@gmail.com

Received 21 October 2017; Accepted 10 January 2018; Published 8 March 2018

Academic Editor: Jose I. Mayordomo

Background. Patients with autoimmune diseases were not evaluated in clinical trials with immune checkpoint inhibitors (ICIs), since a history of immune disorders, such as Guillain–Barré syndrome (GBS) and psoriasis, is one of the major risk factors for the development of immune-related adverse events (irAEs). This risk cannot be defined; therefore, physicians are called to manage these patients in clinical practice. Case Report. We report the case of a 62-year-old male patient affected by metastatic melanoma, with a history of GBS and psoriasis, and treated with sequential ipilimumab, pembrolizumab, and nivolumab, without significant toxicities. Conclusion. This case report supports that although a history of immune disorders is one of the major risk factors for development of irAEs, in some patients, it could be possible to safely administer sequential treatments with ICIs. A proper decision should be made, considering therapeutic options, disease-related risks, and those related to a recurrence of preexisting autoimmune disorders.

1. Introduction

Before starting a treatment with immune checkpoint inhibitors (ICIs), oncologists must identify potential risk factors, such as previous or concomitant dysimmune disorders, that could favour the development of immune-related adverse events (irAEs). Unfortunately, patients with a history of autoimmune diseases were not included in clinical trials; however, after careful baseline assessment, they are more frequent than expected in common clinical practice. In this case, proper management, early diagnosis, and careful pre- and post-treatment monitoring of irAEs are required [1]. IrAEs are reported more frequently with anti-CTLA4 (cytotoxic T-lymphocyte-associated antigen 4) monotherapy rather than with anti-PD-1/PD-L1 (programmed death-1/programmed death-ligand 1) [2]. Immune-mediated polyneuropathies are more frequently related to ipilimumab than to nivolumab or pembrolizumab; they are rare, occurring approximately in 1% of patients and up to 4.5% when referring to all neurological toxicities [2–5]. Guillain–Barré syndrome (GBS) is an acute polyradiculoneuropathy with variable clinical presentation. The pathogenesis of GBS is unclear, but it is well known that it is caused by cellular and humoral immune self-response against peripheral nerves. GBS could be considered as an exceptional irAE with only five cases reported [6–10]. Numerous triggering events have been described, such as infections; GBS can lead to death as a result of complications (infections, thromboembolic events, respiratory failure, and cardiac arrhythmias) in about 5% of cases [11]. Skin disorders are the most frequent toxicity of ICIs; overall incidence of dermatological irAEs appeared to be similar with anti-CTLA4 and anti-PD-1/PD-L1. Considering
any grade, they occur from 10% to 60% (in combination therapy) of patients [3–5, 12–15]. Most cutaneous irAEs are mild, reversible, and easily manageable following guidelines; they are often T-cell-mediated even if the pathophysiology is still unknown. Psoriasis is a multifactorial immune-mediated chronic cutaneous disease, characterized by a wide range of clinical manifestations from mild to severe forms. Worsening and recurrence of psoriasis have been reported during the use of ICIs, with both anti-CTLA4 and anti-PD-1, such as nivolumab [16–20]. Recently, a case series of advanced melanoma patients treated with anti-PD-1 therapy and with preexisting autoimmune disorders has included 2 patients with a history of GBS (none of them experienced a worsening/flare) and 6 patients with a history of psoriasis (3 of them experienced cutaneous irAEs) [21]. We report the case of a 62-year-old male patient, with metastatic melanoma and a history of GBS and psoriasis. The patient was treated with sequential ipilimumab, pembrolizumab, and nivolumab, without significant toxicities or worsening of the preexisting autoimmune disorders. The patient was treated in clinical practice with “in-label” drugs in Italy and provided written informed consent to the proposed treatment; procedures followed in reporting the case are in accordance with the ethical standard of the local responsible committee on human experimentation.

2. Case Presentation

We report the case of a male patient, a smoker, with a history of chronic obstructive lung disease, atrial fibrillation, hypertension, obesity, chronic plaque psoriasis, and Guillain–Barré syndrome (GBS). The diagnosis of GBS dated back to 2002; during a community-acquired pneumonia, a molecular mimetism between bacterial antigens and gangliosides of the nerves’ myelin sheath led to the development of a severe and rapidly progressive muscle weakness with areflexia, till tetraplegia. Electromyography (EMG) confirmed acute, axonal polyneuropathy, with reduced sensory action potential, supporting the diagnosis of the “acute motor and sensory axonal neuropathy” (AMSAN) type of GBS. The patient was hospitalized and successfully treated with intravenous immunoglobulins; he then underwent upper left lobectomy of the lung, in order to excise a bronchiectasis, which was acting as a reservoir of bacteria. Besides a residual neurological injury to his legs, no recurrences were later observed. The patient also reported a history of moderate-to-severe plaque psoriasis, previously treated with cyclosporine A, which was stopped in 2013.

In February 2015, he underwent surgical resection of cutaneous melanoma of the left gluteus, with the following histopathological features: nodular melanoma, ulcerated, Breslow thickness 9 mm, poorly pigmented, 12 mitoses/mm², Clark’s level IV, without regression and intra/peritumoral lymphocytic infiltrate pT4b [22]. Wide surgical excision and sentinel lymph node biopsy were negative for metastatic involvement (pathological stage IIC). In July 2015, positron-emission tomography (PET scan) showed pathological enhancement of the retroperitoneal and left inguinal lymph nodes (standardized uptake values from 2.6 to 22.5); therefore, in September 2015, he underwent wide lymphadenectomy, resulting in 23 out of 42 metastatic lymph nodes; PET scan in December 2015 still demonstrated residual disease in the retroperitoneal lymph nodes. He came to our attention at the age of 62, in quite good clinical conditions, with eastern cooperative oncology group performance status (ECOG-PS) 1. The BRAF mutational analysis (V600) was negative (cobas®≥480 analyzer). The high tumor burden, with LDH more than 2 ULN, and the absence of an actionable BRAF mutation led us to choose a first-line treatment with immune checkpoint inhibitors (ICIs). At that time, the only “in-label” drug in Italy for first-line treatment of BRAF wild-type advanced melanoma patients was ipilimumab (Yervoy®; Bristol-Myers Squibb Pharma EEIG, Uxbridge, United Kingdom). Before starting ipilimumab, we made a careful multidisciplinary assessment with dermatological and neurological evaluation. On dermatological evaluation, the patient presented psoriatic plaques on the trunk and extremities; a baseline EMG was performed that showed the residual functional loss, mainly to the legs (Figure 1).

From December 11, 2015, to February 19, 2016, 4 induction doses of ipilimumab (3 mg/kg every three weeks) were administered without significant toxicities, except development of cutaneous facial vitiligo on the face; psoriatic plaques remained unchanged, and the patient did not develop new neurological symptoms. A CT scan in March 2016 showed an immune-related response of disease (dimensional reduction and intralesional necrosis) and also detected a pulmonary embolism, treated with low molecular weight heparin. In April 2016, the CT scan showed resolution of pulmonary embolism, and neurological evaluation showed no changes, just like the control EMG that was performed.

In June 2016, the CT scan showed progressive disease to the lymph nodes; therefore, the patient underwent a second-line therapy with pembrolizumab (2 mg/kg every three weeks) (Keytruda®; Merck Sharp & Dohme Limited, Hoddesdon, United Kingdom), with only one dose administered, on July 11. After that, he decided to continue the treatment at an outpatient cancer care center closer to his home. From October to November 2016, he received 3 doses of nivolumab (3 mg/kg every two weeks) (Opdivo®; Bristol-Myers Squibb Pharma EEIG, Uxbridge, United Kingdom), without developing significant toxicities, but he died in December 2016 due to the progression of the disease.

3. Discussion

In clinical practice, every patient should be carefully interrogated about the personal and family history of immune disorders because it is one of the few acknowledged risk factors for development of irAEs [1]; following that diagnosis, it is impossible to quantify the risk of worsening/recurrence of the preexisting autoimmune disease. Treatment decision should be made, properly weighing the expected clinical outcome and safety profile in each patient. This kind of patients must be carefully monitored during a treatment with ICIs, in close collaboration with organ-specific consultants, in order to diagnose as soon as possible a potential irAE. Our patient had a history of GBS, a serious and life-threatening disease, and at the same time a moderate psoriasis. The
### Motor nerve conduction study

| R. ext. sciat-popliteal | Onset (ms) | Duration (ms) | Ampl. (mV) | Area (μVs) | Distance (cm) | Speed (m/s) |
|------------------------|------------|---------------|------------|------------|--------------|-------------|
| Ankle                  | 5.9        | 9.2           | 1.8        | 4.0        | 9.0          |             |
| Knee                   | 14.7       | 10.9          | 1.3        | 14.3       | 40.0         | 45.5        |

![Motor nerve conduction study](image)

### Motor nerve conduction study

| R. int. sciat-popliteal | Onset (ms) | Duration (ms) | Ampl. (mV) | Area (μVs) | Distance (cm) | Speed (m/s) |
|-------------------------|------------|---------------|------------|------------|--------------|-------------|
| Inner malleol           | 6.3        | 15.4          | 11.1       | 4.8        | 10.0         | 39.0        |
| Knee                    | 16.5       | 14.2          | 0.8        | 2.3        | 39.0         | 38.6        |

![Motor nerve conduction study](image)

### Motor nerve conduction study

| L. ext. sciat-popliteal | Onset (ms) | Duration (ms) | Ampl. (mV) | Area (μVs) | Distance (cm) | Speed (m/s) |
|-------------------------|------------|---------------|------------|------------|--------------|-------------|
| Ankle                   | 4.5        | 11.0          | 3.6        | 17.0       | 8.0          |             |
| Knee                    | 14.0       | 11.0          | 4.1        | 14.7       | 38.0         | 40.0        |

![Motor nerve conduction study](image)

### Sensitive nerve conduction study

| Right sural | Onset (ms) | Duration (ms) | Ampl. (mV) | Area (μVs) | Distance (cm) | Speed (m/s) |
|-------------|------------|---------------|------------|------------|--------------|-------------|
| Calf        | 3.2        | 2.0           | 12.4       | 12.8       | 14.0         | 34.1        |

![Sensitive nerve conduction study](image)
melanoma-related risk of developing symptoms and of death was higher than that of developing an irAE; therefore, the absence of BRAF actionable mutations forced us to start a first-line treatment with ipilimumab, followed by pembrolizumab and nivolumab after disease progression. All the ICIs were well tolerated, without significant toxicities.

4. Conclusion

This case report supports the idea that, in some patients, it could be possible to safely administer sequential treatments with ICIs, although a history of preexisting immune disorders is one of the major risk factors for the development of irAEs. The decision-making process should include a proper balance between the safety profile and expectations; alternatives should be discussed with patients and families, whose compliance is fundamental to reach a good clinical outcome.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] S. Champiat, O. Lambotte, E. Barreau et al., “Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper,” *Annals of Oncology*, vol. 27, no. 4, pp. 559–574, 2016.

[2] B. El Osta, F. Hu, R. Sadek, R. Chintalapally, and S.-C. Tang, “A meta-analysis of immune-related adverse events (irAE) of immune checkpoint inhibitors (ICI) from cancer clinical trials,” *Annals of Oncology*, vol. 27, no. 6, 2016.

[3] F. S. Hodi, S. J. O’Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” *New England Journal of Medicine*, vol. 363, no. 13, pp. 711–723, 2010.

[4] J. Brahmer, K. L. Reckamp, P. Baas et al., “Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer,” *New England Journal of Medicine*, vol. 373, no. 2, pp. 123–135, 2015.

[5] A. M. M. Eggermont, V. Chiarion-Sileni, J. J. Grob et al., “Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy,” *New England Journal of Medicine*, vol. 375, no. 19, pp. 1845–1855, 2016.

[6] S. Wilgenhof and B. Neyns, “Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient,” *Annals of Oncology*, vol. 22, no. 4, pp. 991–993, 2011.

[7] I. Bot, C. U. Blank, W. Boogerd, and D. Brandsma, “Neurological immune-related adverse events of ipilimumab,” *Practical Neurology*, vol. 13, no. 4, pp. 278–280, 2013.

[8] C. Gaudy-Marqueste, S. Monestier, J. Franques, E. Cantais, M.-A. Richard, and J.-J. Grob, “A severe case of ipilimumab-induced Guillain–Barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis,” *Journal of Immunotherapy*, vol. 36, no. 1, pp. 77-78, 2013.

[9] V. Mukherjee, R. Postelnicu, D. Esaian, and D. Fridman, “An unusual cause of acute respiratory failure,” *American Journal of Respiratory and Critical Care Medicine*, vol. 189, p. A6185, 2014.

[10] W. K. Wu, K. K. Bromman, E. R. Brownie, and R. M. Kauffmann, “Ipilimumab-induced Guillain–Barré syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy,” *Journal of Immunotherapy*, vol. 40, no. 5, pp. 196–199, 2017.

[11] B. van den Berg, C. Walgaard, J. Drenthen et al., “Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis,” *Nature Reviews Neurology*, vol. 10, no. 8, pp. 469–482, 2014.

[12] C. Robert, G. V. Long, B. Brady et al., “Nivolumab in previously untreated melanoma without BRAF mutation,” *New England Journal of Medicine*, vol. 372, no. 4, pp. 320–330, 2015.

[13] J. Larkin, V. Chiarion-Sileni, R. Gonzalez et al., “Combined nivolumab and ipilimumab or monotherapy in untreated melanoma,” *New England Journal of Medicine*, vol. 373, no. 1, pp. 23–34, 2015.

[14] R. S. Herbst, P. Baas, D. W. Kim et al., “Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial,” *The Lancet*, vol. 387, no. 10027, pp. 1540–1550, 2016.

[15] J. R. Brahmer, S. S. Tykodi, L. Chow et al., “Safety and activity of anti-PDL-1 antibody in patients with advanced cancer,” *New England Journal of Medicine*, vol. 366, no. 26, pp. 2455–2465, 2012.

[16] N. Matsumura, M. Ohtsuka, N. Kikuchi, and T. Yamamoto, “Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma,” *Acta Dermato-Venereologica*, vol. 96, no. 2, pp. 259-260, 2016.

[17] Y. Kato, A. Otsuka, Y. Miyachi, and K. Kabashima, “Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma,” *Journal of the European Academy of Dermatology and Venereology*, vol. 30, no. 10, pp. e89-e91, 2016.

[18] M. Ohtsuka, T. Miura, T. Mori, M. Ishikawa, and T. Yamamoto, “Occurrence of psoriasisiform eruption during nivolumab therapy for primary oral mucosal melanoma,” *JAMA Dermatology*, vol. 151, no. 7, pp. 797–799, 2015.

[19] M. B. Totonchy, H. H. Ezaldein, C. J. Ko, and J. N. Choi, “Inverse psoriasisiform eruption during pembrolizumab therapy for metastatic melanoma,” *JAMA Dermatology*, vol. 152, no. 5, pp. 590–592, 2016.

[20] D. B. Johnson, R. J. Sullivan, P. A. Ott et al., “Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders,” *JAMA Oncology*, vol. 2, no. 2, pp. 234–240, 2016.

[21] A. M. Menzies, D. B. Johnson, S. Ramanujam et al., “Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab,” *Annals of Oncology*, vol. 28, no. 2, pp. 368–376, 2017.

[22] S. B. Edge, D. R. Byrd, C. C. Compton et al., *AJCC Cancer Staging Manual*, Springer, New York, NY, USA, 7th edition, 2010.